Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of “Buy” by Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has been given an average rating of “Buy” by the nineteen research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $295.3889.

Several analysts recently issued reports on the stock. Oppenheimer restated an “outperform” rating on shares of Ascendis Pharma A/S in a report on Tuesday, June 9th. Citigroup started coverage on shares of Ascendis Pharma A/S in a research note on Monday, May 18th. They set a “buy” rating and a $355.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $300.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Stifel Nicolaus set a $332.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday, March 4th. Finally, Royal Bank Of Canada boosted their price target on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd.

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jean Jacques Bienaime purchased 400 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were acquired at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the purchase, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 40.00% of the stock is owned by corporate insiders.

Institutional Trading of Ascendis Pharma A/S

A number of large investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP increased its stake in shares of Ascendis Pharma A/S by 114.8% during the first quarter. Seven Fleet Capital Management LP now owns 12,179 shares of the biotechnology company’s stock worth $2,786,000 after buying an additional 6,509 shares during the period. Parallel Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 94.9% during the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after buying an additional 148 shares during the period. Perceptive Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after buying an additional 450,000 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after buying an additional 69 shares during the period. Finally, Eagle Health Investments LP purchased a new stake in shares of Ascendis Pharma A/S during the first quarter worth approximately $19,819,000.

Ascendis Pharma A/S Stock Down 0.0%

Shares of ASND opened at $231.15 on Thursday. The firm has a market cap of $14.42 billion, a P/E ratio of 26.66 and a beta of 0.39. Ascendis Pharma A/S has a 12-month low of $160.86 and a 12-month high of $250.74. The company’s 50-day moving average price is $232.16 and its 200 day moving average price is $224.09. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.11. The company had revenue of $285.45 million during the quarter, compared to analysts’ expectations of $362.47 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post 14.25 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.